1. Home
  2. REVB vs KITT Comparison

REVB vs KITT Comparison

Compare REVB & KITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • KITT
  • Stock Information
  • Founded
  • REVB 2020
  • KITT 2014
  • Country
  • REVB United States
  • KITT United States
  • Employees
  • REVB N/A
  • KITT N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • KITT Industrial Machinery/Components
  • Sector
  • REVB Health Care
  • KITT Industrials
  • Exchange
  • REVB Nasdaq
  • KITT Nasdaq
  • Market Cap
  • REVB 5.4M
  • KITT 5.8M
  • IPO Year
  • REVB N/A
  • KITT N/A
  • Fundamental
  • Price
  • REVB $0.40
  • KITT $2.26
  • Analyst Decision
  • REVB
  • KITT
  • Analyst Count
  • REVB 0
  • KITT 0
  • Target Price
  • REVB N/A
  • KITT N/A
  • AVG Volume (30 Days)
  • REVB 6.8M
  • KITT 17.0M
  • Earning Date
  • REVB 11-08-2024
  • KITT 11-12-2024
  • Dividend Yield
  • REVB N/A
  • KITT N/A
  • EPS Growth
  • REVB N/A
  • KITT N/A
  • EPS
  • REVB N/A
  • KITT N/A
  • Revenue
  • REVB N/A
  • KITT $2,399,852.00
  • Revenue This Year
  • REVB N/A
  • KITT $980.78
  • Revenue Next Year
  • REVB N/A
  • KITT N/A
  • P/E Ratio
  • REVB N/A
  • KITT N/A
  • Revenue Growth
  • REVB N/A
  • KITT N/A
  • 52 Week Low
  • REVB $0.28
  • KITT $0.82
  • 52 Week High
  • REVB $25.26
  • KITT $17.14
  • Technical
  • Relative Strength Index (RSI)
  • REVB 39.87
  • KITT 51.00
  • Support Level
  • REVB $0.39
  • KITT $1.91
  • Resistance Level
  • REVB $0.53
  • KITT $3.44
  • Average True Range (ATR)
  • REVB 0.13
  • KITT 1.02
  • MACD
  • REVB 0.00
  • KITT -0.07
  • Stochastic Oscillator
  • REVB 7.54
  • KITT 16.74

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About KITT Nauticus Robotics Inc.

Nauticus Robotics Inc develops autonomous robots for the ocean industries. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing of related software to both the commercial and defense business sectors. Nauticus' services provide customers with the necessary data collection, analytics, and subsea manipulation capabilities to support and maintain assets while reducing their operational footprint, operating cost, and greenhouse gas emissions, to improve offshore health, safety, and environmental exposure.

Share on Social Networks: